Evaluation of vilazodone for the treatment of depressive and anxiety disorders

  title={Evaluation of vilazodone for the treatment of depressive and anxiety disorders},
  author={Mirella Stuivenga and Erik J. Giltay and Olivia Cools and Laurence Roosens and Hugo M. Neels and Bernard G. C. Sabbe},
  journal={Expert Opinion on Pharmacotherapy},
  pages={251 - 260}
ABSTRACT Introduction: Major Depressive Disorder (MDD) and General Anxiety Disorder (GAD) significantly contribute to the global burden of disease. Vilazodone, a combined serotonin reuptake inhibitor and 5-HT1A partial agonist, is an approved therapy for the treatment of MDD and which has been further investigated for GAD. Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the… 
Panic disorder: A review of treatment options.
  • M. Ziffra
  • Psychology, Medicine
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2021
Treatments with the strongest evidence include SSRIs, other antidepressants, and CBT, and newer interventions approved for the treatment of depression, such as serotonin multimodal agents, esketamine, and rTMS merit further investigation.
Introductory Chapter: Antidepressants - Preclinical, Clinical and Translational Aspects
  • B. Olivier
  • Psychology, Medicine
    Antidepressants - Preclinical, Clinical and Translational Aspects
  • 2019
In 2011 two extensive studies were published about prevalence and associated disability, including the associated disease burden and financial costs, of brain diseases in Europe [1–3]. A shocking
Antidepressant Activity of Euparin: Involvement of Monoaminergic Neurotransmitters and SAT1/NMDAR2B /BDNF Signal Pathway.
Findings demonstrate that Euparin has antidepressant properties, and its mechanism involves the SAT1/NMDAR2B/BDNF signaling pathway.
The binding mode of vilazodone in the human serotonin transporter elucidated by ligand docking and molecular dynamics simulations.
The analysis of the profiles of protein-ligand binding free energies, interaction fingerprints, and conformational rearrangements revealed the binding mode of vilazodone in the hSERT, which was a linear pose unlike the classical antidepressants located in the S1 site of thehSERT.
Differences Between the Prenatal Effects of Fluoxetine or Buspirone Alone or in Combination on Pain and Affective Behaviors in Prenatally Stressed Male and Female Rats
The results indicate that inflammatory pain-like responses integrated at the spinal level in males were more vulnerable to prenatal stress than females, suggesting a more effective prenatal action of buspirone on the development of a descending serotonergic inhibitory system modulating pain in the spinal cord dorsal horn neurons.
Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence
This review presents the experimental evidence of the modulation of the “serotonergic receptosome” in the treatment of anxiety and depression, as well as demonstrating state-of-the-art research related to phytochemicals and these disorders.
University of Birmingham Central 5-HT receptors and their function ; present and future
• Users may freely distribute the URL that is used to identify this publication. • Users may download and/or print one copy of the publication from the University of Birmingham research portal for


The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder
Augmentation of the leading class of antidepressant treatment, selective serotonin reuptake inhibitors (SSRIs), with the 5-HT1A receptor agonist buspirone has been shown to be effective in treating patients that do not respond to initial SSRI therapy, suggesting that newer treatments may improve the clinical picture of MDD.
Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study
This was a positive clinical trial of 20–40 mg/day vilazodone versus placebo in the treatment of GAD, and primary and secondary efficacy parameters were changes from baseline to week 8 in Hamilton Rating Scale for Anxiety and Sheehan Disability Scale total scores, respectively.
The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?
  • L. Dawson
  • Biology, Psychology
    Expert opinion on drug discovery
  • 2013
This review provides the history and preclinical development of vilazodone, highlighting the available data on its putative mechanism of action, potential clinical profile and possible areas for differentiation and suggests preclinical hypotheses will be contextualised with an overview of the key findings from the current clinic data on vilazdone.
The effect of vilazodone on sexual function during the treatment of major depressive disorder.
Results suggest that vilazodone may have a small adverse impact on sexual function in adults with MDD relative to the high prevalence of sexual dysfunction at baseline, and half of men and two thirds of women withMDD hadSexual function improved on average in both vilAZodone and placebo groups.
Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial.
OBJECTIVE To evaluate the efficacy, safety, and tolerability of vilazodone as an acute treatment for generalized anxiety disorder (GAD). Vilazodone is a selective serotonin reuptake inhibitor and
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Vilazodone is effective for the treatment of MDD in adults, with symptom relief starting at 1 week, and is well tolerated at a dose of 40 mg/day, according to the intention-to-treat sample.
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder
Vilazodone was generally safe and well tolerated, with treatment-emergent AEs similar to those in adult patients, and suicidal behavior in adolescent patients could not be confirmed in this study.
Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
Vilazodone 20 and 40 mg/day demonstrated efficacy and tolerability in the treatment of MDD and improved sexual function was seen in all groups; between-group differences were not significant.
A 1-Year, Open-Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder
Vilazodone 40 mg/d for 1 year was safe and well tolerated by adults with major depressive disorder and improvements in Sexual Functioning Questionnaire mean scores improved throughout treatment for both males and females.